EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study

医学 内科学 肺癌 肿瘤科 化疗 转移 脑转移 表皮生长因子受体 外显子 病历 癌症 基因 生物化学 化学
作者
Guangjian Yang,Jun Li,Haiyan Xu,Yaning Yang,Lu Yang,Fei Xu,Bing Xia,Viola Weijia Zhu,Misako Nagasaka,Yan Yang,Yapin Li,Weini Qiu,Jianming Ying,Sai‐Hong Ignatius Ou,Yan Wang
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:145: 186-194 被引量:120
标识
DOI:10.1016/j.lungcan.2020.03.014
摘要

To describe the treatment patterns and outcomes of Chinese non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations in real-world as EGFR ex20ins consist of a diverse group of mutations with limited information on the clinical outcome of these patients treated with chemotherapy or EGFR tyrosine kinase inhibitors (TKIs).Real-world treatment outcomes of Chinese NSCLC patients harboring EGFR ex20ins were retrospectively analyzed based on medical records at different institutions and detailed web-based patient questionnaires.Between March 17, 2018 and December 20, 2018, 165 advanced EGFR ex20ins NSCLC patients treated in 99 hospitals from 26 different regions in China were analyzed. Thirty-nine different molecular variants of EGFR ex20ins were identified with V769_D770insASV being the most common (23.0 %). Central nervous system (CNS) metastasis occurred in 23.0 % of patients at the time of baseline diagnosis. Median progression-free survival (PFS) was significantly longer in patients who received first-line platinum-based chemotherapy (6.4 m; 95 % CI: 5.7-7.1) than all-generation EGFR TKIs (2.9 m; 95 %CI: 1.5-4.3; P < 0.001) or 1st-generation EGFR TKIs (2.0 m; 95 %CI: 0.2-3.8; P < 0.001). Median PFS was numerically longer in patients who received second-line chemotherapy (4.0 m; 95 %CI: 3.2-4.8) than those received second-line EGFR TKIs (2.0 m; 95 %CI: 1.1-2.9; P = 0.342). Patients with CNS metastasis had numerically shorter median PFS than those without CNS metastasis when treated with 1st-line chemotherapy (3.6 m; 95 %CI: 0-8.0 vs. 6.5 m; 95 %CI: 4.9-8.1; P = 0.645) or 1st-line EGFR TKIs (2.0 m; 95 %CI: 0.8-3.2 vs. 2.9 m; 95 %CI: 2.1-3.7; P = 0.058).Chemotherapy is superior to current approved EGFR TKIs as 1st- or 2nd-line treatment of EGFR ex20ins mutations. CNS metastasis conferred numerically shorter PFS with chemotherapy or EGFR TKIs treatment. Targeted agent against EGFR ex20ins with CNS activity is urgently needed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
vbmc发布了新的文献求助30
2秒前
4秒前
5秒前
顾矜的应助被俏皮诺言采纳,获得10
5秒前
5秒前
cdercder的应助被tlc_191026采纳,获得30
9秒前
XY完成签到,获得积分20
9秒前
darkegg完成签到,获得积分10
10秒前
10秒前
10秒前
赵医生完成签到,获得积分10
10秒前
水弘的应助被陶醉的筮采纳,获得10
11秒前
daomaihu发布了新的文献求助100
11秒前
My_magnum_opus给gaoxueli的求助进行了留言
11秒前
xiaolizi发布了新的文献求助30
12秒前
852的应助被1192237414采纳,获得10
13秒前
赵医生发布了新的文献求助10
13秒前
Krositon发布了新的文献求助10
13秒前
14秒前
情怀的应助被panada采纳,获得10
14秒前
WEN完成签到,获得积分10
14秒前
Lucas的应助被Jonathan采纳,获得10
14秒前
小冯完成签到,获得积分10
15秒前
15秒前
matou发布了新的文献求助20
17秒前
Tinker完成签到,获得积分10
17秒前
18秒前
李仟亿发布了新的文献求助10
19秒前
19秒前
刘雨森完成签到,获得积分10
20秒前
Tink完成签到,获得积分0
20秒前
21秒前
水弘的应助被谦让的烨磊采纳,获得10
22秒前
思源的应助被野性的懿轩采纳,获得10
22秒前
人人人完成签到,获得积分10
22秒前
daomaihu发布了新的文献求助100
23秒前
酱鱼完成签到,获得积分10
23秒前
23秒前
Wangdx完成签到 ,获得积分10
23秒前
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183508
求助须知:如何正确求助?哪些是违规求助? 9572862
关于积分的说明 21827639
捐赠科研通 7780681
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480405